This inventor holds 1 USPTO granted patent. Top assignee: Ono Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Calum Macleod: Innovator in KDM5 Inhibitory Compounds
Introduction
Calum Macleod is a notable inventor based in Saffron Walden, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that exhibit KDM5 inhibitory activity. His work is crucial in the fight against various diseases, including cancer, Huntington's disease, and Alzheimer's disease.
Latest Patents
Calum Macleod holds 1 patent for a compound having KDM5 inhibitory activity and its pharmaceutical use. The patent describes a KDM5 inhibitor represented by a specific general formula, where all symbols are defined in the specification. This compound is recognized for its potential as a prophylactic and therapeutic agent for serious health conditions.
Career Highlights
Calum Macleod is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His expertise in KDM5 inhibitors positions him as a valuable asset in the development of new therapeutic agents.
Collaborations
Throughout his career, Calum has collaborated with esteemed colleagues such as Akito Kakuuchi and Shuhei Umemura. These partnerships enhance the research and development efforts in the field of pharmaceuticals.
Conclusion
Calum Macleod's work in developing KDM5 inhibitors showcases his commitment to advancing medical science. His contributions are vital in addressing critical health challenges, and his innovative spirit continues to inspire progress in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile